Navigation Links
Genmab Announces Upcoming Ofatumumab Studies
Date:8/25/2008

at least an objective response or stable disease during a 24 week treatment period of ofatumumab.Eligible patients will receive one infusion of ofatumumab at 300 mg followed by 7 once weekly infusions at 2000 mg. Maintenance treatment will consist of 24 once monthly infusions of 2000 mg of ofatumumab.The primary objective of this study is to estimate the proportion of objective responses over 52 weeks.

Phase II NHL ofatumumab retreatment and maintenance study This study will examine the retreatment and maintenance treatment of refractory follicular NHL patients who participated in the ongoing Phase III NHL study and had disease progression following at least 6 months objective response to or stable disease on ofatumumab.Eligible patients will receive one infusion of ofatumumab at 300 mg followed by 7 once weekly infusions at 1000 mg. Maintenance treatment will consist of one 1000 mg infusion every two months for two years.The primary objective of this study is to evaluate the safety of ofatumumab retreatment and maintenance treatment.

Phase I study in Japan This open-label study will include a maximum of 12 patients with relapsed/refractory follicular NHL and at least 1 CLL patient who will be divided into 2 cohorts of 3 or 6 patients each.Patients will receive one infusion of ofatumumab at 300 mg followed by seven weekly infusions of 500 or 1000 mg of ofatumumab.Safety at the 500 mg dose level of ofatumumab will be examined before progressing to the 1000 mg dose level.The primary objective of the study is to evaluate the safety and tolerability of ofatumumab in Japanese relapsed/refractory follicular NHL and CLL patients.The primary endpoint of the study is safety.

Ofatumumab is an investigational new generation human monoclonal antibody that targets a distinct, membrane proximal, small loop epitope (specific antibody binding site) of the CD20 molecule on B cells. Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DAHANCA Initiates Head and Neck Cancer Study With Genmabs HuMax-EGFr
2. Bionomics Achieves US$1 Million Milestone Payment from Genmab
3. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
4. Genmab Announces Updates on Phase III Cancer Studies
5. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
6. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
7. Genmab Reaches Milestone in Ofatumumab Collaboration
8. Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study
9. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR ... JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ... ABBV ) today announced financial results for the ... was another very strong quarter for AbbVie, as we delivered ... announced plans to merge with Shire, a strategic action that ...
(Date:7/25/2014)... -- Dr. Michael Gabriel of a prominent ... recent study, which shows how grief in pregnancy may cause ... According to US News , "Unborn ... than others to grow up overweight or obese, even if ... two specific types of stress that caused obesity: "Children whose ...
(Date:7/24/2014)... July 24, 2014  Parnell Pharmaceuticals Holdings Ltd ... will be added to Parnell,s already extensive pipeline ... Ltd, a biotechnology company. The compounds now known ... promise in bone regeneration and dermal regeneration, respectively. ... compounds for the veterinary market with the potential ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
(Date:7/26/2014)... Earlier this week, the big announcement that fans of music was ... iHeartRadio Music Festival on Sept. 19 and 20 from the ... of music will have an act they are excited to see ... of Taylor Swift, as well as Zac Brown Band and Eric ... Grande, and Iggy Azalea, while R&B fans will be excited to ...
(Date:7/26/2014)... gas chromatography reagents report defines and segments the concerned market ... chromatography reagents market in Europe is valued at $ 314.8 ... $445.5 million by 2018, at a CAGR of 8.6 %, ... the European gas chromatography reagents market, to get an idea ... glimpse of the segmentation of gas chromatography reagents market in ...
(Date:7/26/2014)... 26, 2014 As reported by ... changing based on 3 factors: smaller spaces, multi-generational access, ... bathroom trend of 2014 lists, including this article ... Amerec , a leading manufacturer of steam bath ... largely due to smaller spaces and an effort to ...
(Date:7/26/2014)... New York, New York (PRWEB) July 26, 2014 ... continue to be filed in U.S. courts, Bernstein ... calling on federal health regulators to ban uterine morcellation. ... individuals include a 46-year-old mother of four from California ... of uterine cancer called leiomyosarcoma just 10 days after ...
(Date:7/26/2014)... July 26, 2014 We’ve all ... the playing field; however, concussions in the workplace ... occupations with the highest risk of head injury ...     Firefighters ,     Police officers ,     Race ...     Delivery personnel , “Most ...
Breaking Medicine News(10 mins):Health News:iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival for Sept. 19 & 20th 2Health News:iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival for Sept. 19 & 20th 3Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 5Health News:Amerec Finds Bathroom Design Trends Change Based on Water Consumption and Other Factors 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 4Health News:KORT Physical Therapists Take the Mystery Out of Identifying and Treating Workplace Head Injuries 2Health News:KORT Physical Therapists Take the Mystery Out of Identifying and Treating Workplace Head Injuries 3
... targeted searches to ob/gyn specialty-specific ... patient care and practice management, ... (http://www.OBGManagement.com ), a leader in the field of obstetrics ... latest search engine tool: OBGfindit.com (http://www.OBGfindit.com )., ...
... discovered a new perspective in the study of infectious ... looking at an organism and how it works within ... published in Environmental Microbiology, Dr Carla Pruzzo, Dr Luigi ... bacteria and its interaction with the environment and found ...
... Sharp Rise in Gonorrhea Cases, HARRISBURG, Pa., May 2 ... of Gonorrhea last year in Delaware County,the Pennsylvania Department of ... and 24 be routinely screened for the,disease, as well as ... to 921 in 2007 from 513,the year before., Of ...
... (Nasdaq:,WBMD) and HLTH Corporation (Nasdaq: HLTH ) today ... the Third Annual Needham & Company,Internet & Digital Media ... ET., Investors, analysts and the general public are ... presentation over the Internet. The broadcast,can be accessed at ...
... Lupus Foundation of,America joins a coalition of approximately 100 ... May 10. More than 1.5 million,Americans and at least ... struggle daily with the often-debilitating health,consequences of the chronic ... an unbalanced immune system that can become,destructive to any ...
... DIEGO, May 2 /PRNewswire-USNewswire/ - It is the cosmetic ... from their hips and thighs and,redistributing it to their ... or effective. Fat grafting for breast enhancement will be,discussed ... American Society,for Aesthetic Plastic Surgery (ASAPS) being held at ...
Cached Medicine News:Health News:OBGManagement.com and Convera(R) Launch Search Site for Physicians in the ObGyn Specialty 2Health News:Lupus Organizations Issue International Call-to-Action to Combat Disease Affecting Five Million People 2Health News:Breast Enhancement With Fat: Pros and Cons 2Health News:Breast Enhancement With Fat: Pros and Cons 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: